Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.
Jérôme HadjadjYann NguyenDalila MouloudjRim BourguibaMael HeibligHassina AlouiChloe McAvoyValentin LacombeSamuel ArdoisCampochiaro CorradoAlexandre MariaCyrille CoustalThibault ComontEstibaliz LazaroFrancois LifermannGuillaume Le GuennoHervé LobbesVincent GrobostRoderau OuthJulien CampagneAnais Dor-EtienneAlice GarnierYvan JamillouxAntoine DossierMaxime SamsonSylvain AudiaBarbara NicolasAlexis MathianBaptiste de MalepradeBenjamin De Sainte-MarieBenoit FaucherJean-David BouazizJonathan BronerCyril DumainCarole AntoineBenjamin CarpentierBrice CastelCeline Lartigau-RoussinEtienne CrickxGeoffroy VolleDamien FayardPaul DeckerThomas MoulinetAnaël DumontAlexandre NguyenAchille AoubaJean-Philippe MartellosioMatthieu LevavasseurSebastien PuigrenierPascale AntoineJean-Thomas GiraudOlivier HermineCarole LacoutNihal MartisJean-Denis KaramFrancois ChassetLaurent ArnaudPaola MarianettiChristophe DelignyThibaud ChazalPascal Woaye-HuneMurielle Roux-SauvatAurore MeyerPierre SujobertPierre HirschNoemie AbisrorPierre FenauxOlivier KosmiderVincent JachietOlivier FainBenjamin TerrierArsenne MekinianStéphanie Ducharme-Bénardnull nullPublished in: Annals of the rheumatic diseases (2024)
This study shows the benefit of JAKi and IL-6 inhibitors, whereas other therapies have lower efficacy. These results need to be confirmed in prospective trials.
Keyphrases